» Articles » PMID: 14556988

Differential Expression of Stem Cell Mobilization-associated Molecules on Multi-lineage Cells from Adipose Tissue and Bone Marrow

Overview
Journal Immunol Lett
Date 2003 Oct 15
PMID 14556988
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

Our laboratory has characterized a population of stromal cells obtained from adipose tissue termed processed lipoaspirate cells (PLAs). PLAs, like bone-marrow derived mesenchymal stem cells (BM-MSCs), have the capacity to differentiate along the adipogenic, osteogenic, chondrogenic, and myogenic lineages, In order to better characterize these two multi-lineage populations, we examined the surface phenotype of both bone marrow and adipose tissue-derived cells from five patients undergoing surgery. PLA and BM-MSC cells were isolated, subcultivated, and evaluated for cell surface marker expression using flow cytometry. PLA and BM-MSC cells both expressed CD13, CD29, CD44, CD90, CD105, SH-3, and STRO-1. Differences in expression were noted for cell adhesion molecules CD49d (Integrin alpha4), CD54 (ICAM-1), CD34, and CD106 (VCAM-1). While markedly similar, the surface phenotypes of PLA and BM-MSC cells are distinct for several cell adhesion molecules implicated in hematopoietic stem cell homing, mobilization, and proliferation.

Citing Articles

Mesenchymal Stem Cells in Cancer Therapy.

Baran Z, Cetinkaya M, Baran Y Adv Exp Med Biol. 2024; 1474():149-177.

PMID: 39470980 DOI: 10.1007/5584_2024_824.


Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges.

Shan Y, Zhang M, Tao E, Wang J, Wei N, Lu Y Signal Transduct Target Ther. 2024; 9(1):242.

PMID: 39271680 PMC: 11399464. DOI: 10.1038/s41392-024-01936-8.


Efficacy and safety of autologous or allogeneic mesenchymal stromal cells from adult adipose tissue expanded and combined with tricalcium phosphate biomaterial for the surgical treatment of atrophic nonunion of long bones: a phase II clinical trial.

Orozco Delclos L, Soler Rich R, Arriaza Loureda R, Moreno Garcia A, Gomez Barrena E J Transl Med. 2024; 22(1):493.

PMID: 38789992 PMC: 11127443. DOI: 10.1186/s12967-024-05280-x.


A Powerful Tool in the Treatment of Myocardial Ischemia-Reperfusion Injury: Natural and Nanoscale Modified Small Extracellular Vesicles Derived from Mesenchymal Stem Cells.

Zhou Z, Zhang X, Wang S, Wang X, Mao J Int J Nanomedicine. 2024; 18:8099-8112.

PMID: 38164265 PMC: 10758182. DOI: 10.2147/IJN.S443716.


The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy.

Li J, Wu Z, Zhao L, Liu Y, Su Y, Gong X Stem Cell Res Ther. 2023; 14(1):381.

PMID: 38124129 PMC: 10734083. DOI: 10.1186/s13287-023-03587-y.